MiNK Therapeutics Awarded Prestigious NIAID Grant to Advance Allo-iNKT Cell Therapy for Prevention of GvHD in Stem Cell Transplant Patients
Summary
MiNK Therapeutics received a grant from NIAID to support development of its allo-iNKT cell therapy platform. The program targets prevention and treatment of graft-versus-host disease after hematopoietic stem cell transplantation. MiNK will work with the University of Wisconsin to advance preclinical and clinical research. The company says the award validates its platform and helps speed development in a high-priority unmet need area.
Classifications
industries
No industries detected
applications
No applications detected
AskAI Classifications
Labels
No AI classifications detected